Tokio Marine Asset Management 13F: Exits Bio-Techne (TECH) Stake
Key Points
- Tokio Marine Asset Management sold out of its 49,600 shares of Bio-Techne, a move valued at approximately $3.6 million.
- The stock, recently trading around $72.69, has seen analysts downgrade their ratings, with several firms setting a price target of $73.00.
- Bio-Techne has a dividend rate of $0.32 and will report its next earnings on November 9, 2026.
Get Bio-Techne text alerts
We text you when insiders, Congress, analysts or big funds move on $TECH.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Bio-Techne Corporation alert may contain errors. Disclosures
Tokio Marine Asset Management sold its entire stake of 49,600 shares in Bio-Techne Corporation (TECH) in a filing on October 26, 2026. This move is valued at approximately $3.6 million. The filing details can be found in the fund's latest Form 13F with the SEC.
TECH
Bio-Techne Corporation
Where Bio-Techne Fits in Tokio Marine Asset Management's Portfolio
This sale represents a 100% decrease in its position, which was ranked 503 out of the fund's holdings. The total reported value of Tokio Marine's 13F was about $1.46 billion.
Other Institutional Activity in Bio-Techne
HBK Investments L P increased its position in Bio-Techne by 3,412,500 shares, bringing its total to 6,825,000 shares worth approximately $496.1 million.
Bio-Techne Corporation Stock Up 0.1%
Bio-Techne shares have recently traded around $72.69, just below the analysts' consensus price target of $73.00. The stock is facing some pressure as analysts have downgraded their ratings recently.
Recent Earnings
For the trailing twelve months, Bio-Techne reported revenue of approximately $1.22 billion and earnings per share of $1.16. The company has a net margin of 15.0% and a return on equity of 9.0%. The next earnings report is scheduled for November 9, 2026.
Dividend
Bio-Techne pays an annual dividend of $0.32 per share, with a payout ratio of 27.6%.
Insider Buying and Selling at Bio-Techne Corporation
Two insider transactions were reported earlier this year. Director Amy E. Herr sold 6,636 shares at an average price of $48.28 on May 8, 2026, valued at $320,386. She also sold 1,976 shares at $59.10 on February 17, 2026, worth $116,791.
Analysts Set New Price Targets
On June 29, 2026, Citigroup downgraded Bio-Techne to a Neutral rating with a price target of $73.00, up from $70.00. On June 30, 2026, TD Cowen also downgraded the stock to Hold with the same price target of $73.00. RBC Capital and Wells Fargo followed suit with their downgrades, both setting a target of $73.00 as well.
About Bio-Techne
Bio-Techne Corporation develops and sells life science reagents, instruments, and services for research and diagnostics. With a focus on biotechnology, the company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. This sale by Tokio Marine Asset Management comes as the company prepares to report earnings next month.
Bottom Line
Investors will be watching for Bio-Techne's upcoming earnings report on November 9, 2026, to gauge its performance amidst recent analyst downgrades and stock activity.
Related Filing Alerts
Source: Tokio Marine Asset Management's 13F filing on $TECH (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts